Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis

被引：0
|
作者：
Bhatia, Neal [1 ]
Vasquez, J. Gabriel [2 ]
Schenkel, Brad [3 ]
Rozzo, Stephen J. [3 ]
Heim, Jayme [2 ]
机构：
[1] Therapeut Clin Res, San Diego, CA USA
[2] West Michigan Dermatol, Grandville, MI USA
[3] Sun Pharmaceut Ind Inc, Princeton, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42281
引用
收藏
页码：AB72 / AB72
页数：1
相关论文
共 50 条
  • [21] Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: Week 28 interim analysis of a Phase 4 study
    Bhatia, Neal
    Heim, Jayme
    Torres, Monique
    Beute, Paulita
    Rozzo, Stephen J.
    Vasquez, J. Gabriel
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 6 - 7
  • [22] Real-World Effectiveness and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Adult Patients: A 52-Week Multicenter Retrospective Study
    Yeung, Jensen
    Sood, Siddhartha
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2024,
  • [23] Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study
    Caldarola, Giacomo
    Galluzzo, Marco
    Bernardini, Nicoletta
    Calabrese, Laura
    Grimaldi, Marta
    Moretta, Gaia
    Pagnanelli, Gianluca
    Shumak, Ruslana Gaeta
    Talamonti, Marina
    Tofani, Lorenzo
    Pallotta, Sabatino
    Peris, Ketty
    Potenza, Concetta
    De Simone, Clara
    Campione, Elena
    DERMATOLOGIC THERAPY, 2022, 35 (06)
  • [24] Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate -to -Severe Plaque Psoriasis
    Heim, Jayme
    Vasquez, J. Gabriel
    Bhutani, Tina
    Koo, John
    Mathew, Jacob
    Gogineni, Ranga
    Ferro, Thomas
    Bhatia, Neal
    JOURNAL OF DRUGS IN DERMATOLOGY, 2024, 23 (08) : 612 - 618
  • [25] Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa
    Kok, Yonatan
    Nicolopoulos, Jenny
    Howard, Anne
    Varigos, George
    Kern, Johannes
    Dolianitis, Con
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2020, 61 (04) : E488 - E490
  • [26] Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature
    Kory P. Schrom
    Avi Bitterman
    Neil J. Korman
    Current Dermatology Reports, 2019, 8 : 6 - 13
  • [27] Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature
    Schrom, Kory P.
    Bitterman, Avi
    Korman, Neil J.
    CURRENT DERMATOLOGY REPORTS, 2019, 8 (01) : 6 - 13
  • [28] Predictors of response to tildrakizumab for moderate-to-severe chronic plaque psoriasis
    Blauvelt, Andrew
    Reich, Kristian
    Papp, Kim A.
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Gooderham, Melinda
    Li, Qing
    Cichanowitz, Nicole
    la Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB226 - AB226
  • [29] Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
    Jia, Xiaoying
    Zhao, Yang
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Mendelsohn, Alan M.
    Lowry, Simon
    Feldman, Steve
    Wu, Jashin J.
    Armstrong, April W.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 740 - 748
  • [30] Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
    Ruggiero, Angelo
    Fabbrocicni, Gabriella
    Cacciapuoti, Sara
    Potestio, Luca
    Gallo, Lucia
    Megna, Matteo
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 529 - 536
12345